ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Cambrex invests more in North Carolina

by Rick Mullin
September 29, 2018 | APPEARED IN VOLUME 96, ISSUE 39

 

09639-buscon13-pharmacore.jpg
Credit: Cambrex
Cambrex acquired the High Point facility in 2016.

In response to growing demand for clinical supply of active pharmaceutical ingredients, Cambrex will add kilogram- and pilot-scale manufacturing capacity at its High Point, N.C., facility. Cambrex will acquire a 3,250-m2 facility it currently leases as well as an adjacent 4,200-m2 building. Cambrex got the High Point facility in 2016 with the $25 million acquisition of PharmaCore. Since last year it has added a 1,000-m2 analytical laboratory at the site and completed a clinical-scale manufacturing suite.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment